Harrow, Inc. (NASDAQ:HROW) Given Average Recommendation of “Moderate Buy” by Analysts

Harrow, Inc. (NASDAQ:HROW) has been assigned a consensus recommendation of “Moderate Buy” from the eleven brokerages that are presently covering the stock, Marketbeat Ratings reports. One investment analyst has rated the stock with a sell rating, two have assigned a hold rating and eight have assigned a buy rating to the company. The average 1 year target price among analysts that have issued a report on the stock in the last year is $69.8571.

HROW has been the topic of several research analyst reports. William Blair restated an “outperform” rating on shares of Harrow in a research note on Tuesday, March 3rd. Cantor Fitzgerald reduced their price target on shares of Harrow from $94.00 to $91.00 and set an “overweight” rating for the company in a research note on Wednesday, March 4th. Weiss Ratings cut shares of Harrow from a “sell (d-)” rating to a “sell (e+)” rating in a report on Wednesday, April 22nd. HC Wainwright restated a “buy” rating and set a $70.00 price objective on shares of Harrow in a research report on Thursday, March 19th. Finally, B. Riley Financial restated a “buy” rating and issued a $65.00 target price (down from $74.00) on shares of Harrow in a report on Tuesday, April 7th.

Harrow Trading Up 0.9%

Shares of NASDAQ:HROW opened at $40.90 on Friday. The company has a debt-to-equity ratio of 4.67, a current ratio of 2.20 and a quick ratio of 2.06. Harrow has a 1 year low of $21.12 and a 1 year high of $54.85. The company has a market cap of $1.52 billion, a P/E ratio of -240.57 and a beta of 0.34. The stock’s fifty day moving average price is $39.16 and its 200-day moving average price is $42.41.

Hedge Funds Weigh In On Harrow

Several hedge funds and other institutional investors have recently modified their holdings of HROW. Vanguard Group Inc. grew its holdings in shares of Harrow by 2.7% in the fourth quarter. Vanguard Group Inc. now owns 1,921,683 shares of the company’s stock worth $94,162,000 after acquiring an additional 50,889 shares during the period. Geode Capital Management LLC lifted its holdings in Harrow by 1.2% in the fourth quarter. Geode Capital Management LLC now owns 785,089 shares of the company’s stock valued at $38,477,000 after acquiring an additional 9,445 shares during the period. Penn Capital Management Company LLC lifted its holdings in Harrow by 20.5% in the fourth quarter. Penn Capital Management Company LLC now owns 392,067 shares of the company’s stock valued at $19,257,000 after acquiring an additional 66,589 shares during the period. Dimensional Fund Advisors LP boosted its position in Harrow by 32.2% in the fourth quarter. Dimensional Fund Advisors LP now owns 370,548 shares of the company’s stock worth $18,159,000 after purchasing an additional 90,331 shares during the last quarter. Finally, Goldman Sachs Group Inc. boosted its position in Harrow by 28.1% in the fourth quarter. Goldman Sachs Group Inc. now owns 366,533 shares of the company’s stock worth $17,960,000 after purchasing an additional 80,368 shares during the last quarter. 72.76% of the stock is owned by institutional investors.

Harrow Company Profile

Harrow Health, Inc (NASDAQ: HROW) is a U.S.-based commercial-stage biopharmaceutical company specializing in ophthalmic therapeutics and diagnostics. The company focuses on the development, manufacturing and distribution of proprietary, generic and branded eye care products designed to treat a range of ocular conditions, including glaucoma, ocular hypertension, dry eye disease and other anterior segment disorders.

Through its wholly owned affiliate ImprimisRx, Harrow Health offers a direct-to-physician model for customized formulations as well as low-cost generic alternatives.